QueQuoin Holdings

QueQuoin Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of therapies for rare and orphan diseases, particularly in the field of dermatology. The company's lead product candidate, QNQ-101, is a topical formulation of a small molecule serine protease inhibitor designed to treat Netherton Syndrome. QueQuoin is also advancing a pipeline of programs for other severe skin disorders, including Autosomal Recessive Congenital Ichthyosis and Dystrophic Epidermolysis Bullosa. The company leverages its expertise in topical drug delivery to address the significant unmet medical needs of patients suffering from these debilitating genetic conditions.